Bactroban and Nephrogenic systemic fibrosis - a phase IV clinical study of FDA data

Summary:

Nephrogenic systemic fibrosis is reported as a side effect among people who take Bactroban (mupirocin), especially for people who are male, 30-39 old, also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Nephrogenic systemic fibrosis when taking Bactroban. It is created by eHealthMe based on reports of 4,919 people who have side effects when taking Bactroban from the FDA, and is updated regularly.

What is Bactroban?

Bactroban has active ingredients of mupirocin. It is often used in infection. eHealthMe is studying from 4,967 Bactroban users. Check the latest studies of Bactroban.

What is Nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease) is found to be associated with 505 drugs and 673 conditions by eHealthMe. Check the latest studies of Nephrogenic systemic fibrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

4,919 people reported to have side effects when taking Bactroban.
Among them, 15 people (0.3%) have Nephrogenic systemic fibrosis.

Could Bactroban cause Nephrogenic systemic fibrosis?

Among these 15 people:

What is the gender of people who have Nephrogenic systemic fibrosis when taking Bactroban? *

female: 23.08 %
male: 76.92 %

What is the age of people who have Nephrogenic systemic fibrosis when taking Bactroban? *

What are other drugs people take besides Bactroban? *

What are other side effects people have besides Nephrogenic systemic fibrosis? *

Stress And Anxiety: 12 people, 80.00%
Pain: 10 people, 66.67%
Mobility Decreased (ability to move is reduced): 10 people, 66.67%
Joint Range Of Motion Decreased (disease of joint movement): 10 people, 66.67%
Skin Induration (an abnormally hard spot or area on the skin): 10 people, 66.67%
Joint Contracture (a permanent shortening of a muscle or joint): 9 people, 60.00%
Scar: 9 people, 60.00%
Skin Fibrosis (fibrous tissue formation on skin): 8 people, 53.33%
Emotional Distress: 8 people, 53.33%
Hypoaesthesia (reduced sense of touch or sensation): 8 people, 53.33%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 10 people, 66.67%
Pain: 6 people, 40.00%
Nuclear Magnetic Resonance Imaging Abdominal: 5 people, 33.33%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 5 people, 33.33%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 26.67%
Nephrogenic Anaemia (anaemia due to kidney disease): 4 people, 26.67%
Nausea (feeling of having an urge to vomit): 4 people, 26.67%
Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 13.33%
Renal Disorder (kidney disease): 2 people, 13.33%
Cardiac Disorder: 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Bactroban and have Nephrogenic systemic fibrosis?

- Check whether Nephrogenic systemic fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bactroban:

Bactroban (4,967 reports)

Browse all side effects of Bactroban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (505 drugs)

Browse all the conditions that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (673 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mupirocin (the active ingredients of Bactroban) and Bactroban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.